首页> 外国专利> METHOD FOR DESIGNING A PERSONALISED THERAPY FOR AN INDIVIDUAL SUFFERING FROM CISPLATIN-RESISTANT LUNG CANCER

METHOD FOR DESIGNING A PERSONALISED THERAPY FOR AN INDIVIDUAL SUFFERING FROM CISPLATIN-RESISTANT LUNG CANCER

机译：个性化针对抗西拉汀肺癌的个体患者的治疗方法

页面导航

摘要
著录项
相似文献

摘要

The present invention relates to an in vitro method for designing a personalised therapy for an individual suffering from cisplatin-resistant lung cancer, comprising determining the expression level of the PGC-1 alpha gene before and after the treatment with cisplatin, wherein if the expression level of said gene is greater after than before the treatment with cisplatin, the therapy then comprises the administration of a compound intended to reduce the OXPHOS function.

机译：本发明涉及一种用于设计针对顺铂耐药性肺癌的个体的个性化疗法的体外方法，该方法包括确定在用环磷酰胺治疗的前后PGC-1α基因的表达水平。顺铂，其中如果所述基因的表达水平在比顺铂治疗之前更高，则该治疗包括给予旨在降低OXPHOS功能的化合物。 展开▼

著录项

公开/公告号WO2019002655A1

专利类型

公开/公告日2019-01-03

原文格式PDF

申请/专利权人 FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA;UNIVERSIDAD AUTÓNOMA DE MADRID;
展开▼

申请/专利号WO2018ES70463

发明设计人 PROVENCIO PULLA MARIANO;CRUZ BERMÚDEZ ALBERTO;
展开▼

申请日2018-06-28

分类号C12Q1/6886;

国家 WO

入库时间 2022-08-21 11:57:33

相似文献

专利

外文文献

中文文献

1. 紫杉醇与长春西汀联合用药在制备治疗肺癌药物中的应用 [P] . 中国专利： CN113209094A . 2021-08-06

2. 一种他达拉非和盐酸达泊西汀混合片的制备方法 [P] . 中国专利： CN113181185A . 2021-07-30

3. Method for designing personalized therapy for an individual suffering from lung cancer and treated with cisplatin (Machine-translation by Google Translate, not legally binding) [P] . ES2695449A1 . 2019-01-04

机译：为患有肺癌并接受顺铂治疗的个体设计个性化治疗的方法（通过Google Translate进行机器翻译，不具有法律约束力）

4. ccr5 antagonist, method for determining whether a human individual having prostate cancer is suffering from or at risk of metastasis, to identify a ccr5 antagonist, method for determining whether a human individual having prostate cancer is suffering from or under risk of developing metastasis, to identify a candidate compound, to produce in vitro primary epithelial cells, to diagnose prostate cancer, to select a treatment for an individual having a prostate cancer / tumor, cell line, and, animal model [P] . BR112013023050A8 . 2018-09-25

机译： ccr5拮抗剂，用于确定患有前列腺癌的人是否患有转移瘤或处于转移危险中的方法，以鉴定ccr5拮抗剂，用于确定患有前列腺癌的人的个体患有转移瘤或处于转移危险中的方法，以鉴定一种候选化合物，用于产生体外原代上皮细胞，诊断前列腺癌，为患有前列腺癌/肿瘤，细胞系和动物模型的个体选择治疗方法

5. nox inhibitor for use in the treatment of solid tumor cancers or haematological neoplasms, pharmaceutical composition, and, methods to treat an individual suffering from solid tumor cancer or haematological neoplasia, to restore or increase responsiveness to anticancer immunotherapy and to restore or increase responsiveness to anticancer antiangiogenesis [P] . BR112020008440A2 . 2020-10-06

机译：用于治疗实体瘤癌症或血液肿瘤的nox抑制剂，药物组合物以及治疗患有实体瘤癌症或血液肿瘤的个体，恢复或增加对抗癌免疫疗法的反应性以及恢复或增加对抗癌反应性的方法抗血管生成

1. Impact of Cardiac Dose on Overall Survival in Lung Stereotactic Body Radiotherapy (SBRT) Compared to Conventionally Fractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) [J] . Justin D. Anderson, Jiuyun Hu, Jing Li, 癌症治疗（英文） . 2021,第007期

2. DETECTING EXPRESSION OF MRP-1/CD9 mRNA IN LUNG CANCERS USING TISSUE MICROARRAYS AND FLUORESCENCE IN SITU HYBRIDIZATION METHODS [J] . WANG Xin-yun, LIU Ting, LI Yan, 中国癌症研究（英文版） . 2005,第003期

3. Deactivation of cisplatin-resistant human lung/ovary cancer cells with pyropheophorbide-a methyl ester-photodynamic therapy (vol 18, pg 984, 2018) [J] . Qian Guanhua, Wang L., Zheng Xueling, Cancer biology & therapy . 2018,第10a12期

4. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling [J] . Wang Hai-Jing, Yang Zai-Xing, Dai Xiao-Tian, Apoptosis: An international journal on programmed cell death . 2017,第9期

5. Deactivation of cisplatin-resistant human lung/ovary cancer cells with pyropheophorbide-alpha methyl ester-photodynamic therapy [J] . Qian Guanhua, Wang Li, Zheng Xueling, Cancer biology & therapy . 2017,第10a12期

6. An Automated Method for Registration and Perfusion Analysis of Pulmonary CT Data for Evaluating Response to Radiotherapy in Patient with Non Small Cell Lung Cancer [C] . Yu-Tzu Lee, Chi-Hsuan Tsou, Yeun-Chung Chang, Conference on biomedical applications in molecular, structural, and functional imaging . 2013

7. A Novel Method to Evaluate Local Control of Lung Cancer in Stereotactic Body Radiation Therapy (SBRT) Treatment Using 18F-FDG Positron Emission Tomography (PET) [D] . Kathriarachchi, Vindu Wathsala. 2013

8. Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial [O] . Noor Ali, Kate J Lifford, Ben Carter, 2015

9. 18F-FDG PET/CT for Target Volume Contouring in Lung Cancer Radiotherapy (perspective on “Comparison of Different Methods for Delineation of 18F-FDG PET–Positive Tissue for Target Volume Definition in Radiotherapy of Patients with Non–Small Cell Lung Cancer” J Nucl Med. 2005;46:1342–1348) [O] . Martin Stuschke, Christoph Pöttgen 2020

1. Clinical study on concurrent and sequential therapy of intensity modulated radiation therapy (IMRT) combined with NP regimen chemotherapy in the treatment of middle and advanced non-small cell lung cancer [J] . Xiaodong Jiang Da＇an Song Weiming Zhang Jin Wu . 中德临床肿瘤学杂志：英文版 . 2007,第1期

2. BACKGROUND： Vibrio vulnifi cus inside the body could activate the NF-!B signaling pathwayand initiate the inflammatory cascade. The lung is one of the earliest organs affected by sepsisassociated with acute lung injury. High mobility group protein B1 （HMGB1） is an important late-actingpro-infl ammatory cytokine involving in the pathophysiology of sepsis. It is also involved in the injuryprocess in the lung, liver and intestine. There has been no report on the involvement of HMGB1 inVibrio vulnifi cus sepsis-induced lung injury.METHODS： Sixty rats were randomly divided into a normal control group （group A, n=10） anda Vibrio vulnificus sepsis group （group B, n=50）. Sepsis was induced in the rats by subcutaneousinjection of Vibrio vulnificus （concentration 6×108 cfu/mL, volume 0.1 mL/100g）） into the left lowerlimbs. The rats in group B were sacrifi ced separately 1, 6, 12, 24, and 48 hours after the infection.Their lungs were stored as specimens, lung water content was measured, and lung pathology wasobserved under a light microscope. The expressions of the HMGB1 gene and protein in the lungswere detected by RT-PCR and Western blot. Data were analyzed with one-way analysis of variance（ANOVA） and the LSD method for pair-wise comparison between the two groups. P〈0.05 wasconsidered statistically signifi cant.RESULTS： Compared to group A （0.652±0.177）, HMGB1 mRNA expression in the lungs ofgroup B was signifi cantly higher at 0 hour （1.161±0.358, P=0.013）, 24 hours （1.679±0.235, P=0.000）,and 48 hours （1.258±0.274, P=0.004）（P〈0.05）, and peaked at 24 hours. Compared to group A（0.594±0.190）, HMGB1 protein expression at 6 hours （1.408±0.567, P=0.026） after infection wassignificantly increased （P〈0. 05）, and peaked at 24 hours （2.415±1.064, P=0.000） after infection.Compared to group A （0.699±0.054）, lung water content was significantly increased at 6 hours（0.759±0.030, P=0.001）,12 hours （0.767±0.023, P=0.000）, 24 hours （0.771±0.043, P=0.000） and 48hours （0.789±0.137, P=0.000） after infection （P〈0.05）. Compared to group A, pathological changesat 12 hours in group B indicate marked pulmonary vascular congestion, interstitial edema andinfl ammatory infi ltration. Alveolar cavity collapse and boundaries of the alveolar septum could not beclearly identifi ed.CONCLUSION： Vibrio vulnifi cus sepsis can lead to injury in rat lungs, and increased HMGB1expression in lung tissue may be one of the mechanisms for injury from Vibrio vulnifi cus sepsis. [J] . Qiao-meng Qiu ,Zhong-wang Li ,Lu-ming Tang . 世界急诊医学杂志(英文) . 2011,第4期

3. Intralesion and CuradermsupBEC5/supTopical Combination Therapies of Solasodine Rhamnosyl Glycosides Derived from the Eggplant or Devil’s Apple Result in Rapid Removal of Large Skin Cancers. Methods of Treatment Compared [J] . Bill E. Cham . 临床医学国际期刊（英文） . 2012,第2期

4. 度洛西汀与帕罗西汀治疗伴有疼痛症状的抑郁障碍患者的对照研究 [C] . 张艳 ,唐茂芹 . 山东省医学会精神医学专业委员会第十八次学术会议暨山东省康复医学会精神康复专业委员会第十次学术会议 . 2010

5. 阿戈美拉汀和度洛西汀治疗抑郁症的成本效果分析 [A] . 马含情 . 2016